SF
IMRX icon

Summit Financial’s Immuneering IMRX Stock Holding History

Summit Financial’s Portfolio IMRX Stock Details IMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.26M Buy
452,264
+75,515
+20% +$382K 0.02% 606
2026
Q1 		$1.99M Buy
+376,749
New +$1.93M 0.03% 579

Other funds holding IMRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DA
DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Summit Financial's IMRX Position: Q2 2026 in Review

Summit Financial increased its Immuneering (IMRX) stake by 20% in Q2 2026, buying an estimated $382K and bringing the position to 452,264 shares worth $2.26M. The position accounts for 0.02% of the portfolio, ranked #606.

Summit Financial first reported a position in IMRX in Q1 2026 and has held it in 2 quarters since. 112 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

  • Summit Financial held 452,264 shares of Immuneering worth $2.26M as of Q2 2026.
  • Summit Financial bought 75,515 Immuneering shares in Q2 2026, an estimated $382K.
  • Immuneering made up 0.02% of Summit Financial's portfolio in Q2 2026, its #606 holding.
  • Summit Financial first reported a position in Immuneering in Q1 2026 and has held it in 2 quarters since.
  • 112 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Summit Financial's 13F filing for Q2 2026, filed 12 Aug 2026.